Strategies for long-term success in the treatment of HIV infection

JAMA

Volumn 283, Issue 10, 2000, Pages 1329-1334

  Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CROSS RESISTANCE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL TIME; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 0034051154     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.10.1329     Document Type: Article

References (32)

1. Bartlett JG, Chaisson R, Keruly J, Moore R, HAART: one of the most cost-effective therapies of the past decade. In: Programs and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 24380.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al, for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
4. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4 T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
5. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381-390.
6. DHHS Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for use of antiretroviral agents in HIV-infected adults and adolescents, May 1999 revision. Available at: http://hivatis.org. Accessed January 21, 2000.
7. Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice [editorial]. AIDS. 1998;12:453-460.
8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
9. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619-1624.
10. Staszewski S, Morales-Ramirez J, Tashima KT, et al, for the Study 006 Team. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999; 341:1865-1873.
11. Staszewski S, Keiser P, Gathe J, et al. Comparison of antiviral response with abacavir/Combivir to indinavir/Combivir in therapy-naive adults at 48 weeks (CNA3005). In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 505.
12. Federici ME, Lupo S, Cahn P, et al. Hydroxyurea in combination regimens forthe treatment of antiretroviral naïve, HIV-infected adults. In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 287/12235.
13. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
14. Hall CS, Raines CP, Barnett SH, Moore RD, Gallant JE. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS. 1999;13:1207-1212.
15. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23-F28.
16. Zolopa A, Tebas P, Gallant J, et al. The efficacy of ritonavir (RTV)/saquinavir (SQV) antiretroviral therapy (ART) in patients who failed nelfinavir (NFV): a multicenter clinical cohort study. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 2065.
17. Havlir DV, Hellman NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-234.
18. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS. 1998;12: F97-F102.
19. Hirsch MS, Conway B, D'Aquila RT, et al, for the International AIDS Society - USA panel. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA. 1998;279:1984-1991.
20. Zolopa AR, Shafer RW, Warford A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999;131:813-821.
21. Baxter JD, Mayers DL, Wentworth DN, et al. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral treatment. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, III. Abstract LB8.
22. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIR-ADAPT randomised controlled trial. Lancet. 1999; 353:2195-2199.
23. Piketty C, Race E, Castiel P, et al. Phenotypic resistance to protease inhibitors predicts outcome of a five drug combination including ritonavir, saquinavir and efavirenz in patients who failed HAART. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 2068.
24. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999; 282:1135-1141.
25. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999;282:1142-1149.
26. Montaner JS, Harrigan PR, Jahnke NA, et al. Multidrug rescue therapy (MDRT) for HIV-infected individuals with prior virologic failure to multiple regimens - results from two cohorts. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 2067.
27. Miller V, Rottmann C, Hertogs K, et al. MegaHAART, resistance and drug holidays. In: Program and abstracts of the 2nd International Workshop on Salvage Therapy for HIV Infection; May 19-21, 1999; Toronto, Ontario. Abstract 030.
28. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study [letter]. Lancet. 1998;351:723-724.
29. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35-F43.
30. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:701-706.
31. Becker S. Resource utilization in HIV care: the case for the expert provider. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 464.
32. Peters R, Sikorski R. The AIDS Net: HIV/AIDS resources on the World Wide Web. JAMA. 1998;280: 2037-2038.